A Six-Gene Signature Predicts Survival of Patients with Localized Pancreatic Ductal Adenocarcinoma

Abstract excerpt

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) remains a lethal disease. For patients with localized PDAC, surgery is the best option, but with a median survival of less than 2 years and a difficult and prolonged postoperative course for most, there is an urgent need to better identify patients who have the most aggressive disease. METHODS AND FINDINGS: We analyzed the gene expression profiles of primary...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cholangiocarcinoma and Gallbladder Cancer Studies
• Share to Ferroptosis and cancer prognosis
• Share to Pancreatic and Hepatic Oncology Research